The going hasn’t gotten any easier for AxoGen (AXGN).
This up-and-coming med-tech company specializing in nerve repair has
spooked growth investors with regard to its revenue growth rate and
investors have also grown more concerned over the possibility of more
intense competition from companies like Integra (IART) and Baxter (BAX)
in the nerve repair market. While all that’s been going on, there seems
to have been a general shift away from higher-growth (and higher-risk)
stories in the med-tech space.
I’m still bullish on
AxoGen, as I believe it addresses a large and under-served market with
better products, but sentiment won’t turn around overnight. The 30%-plus
long-term revenue growth I expect from AxoGen is hardly conservative,
but I do believe these shares can outperform as surgeons become more
familiar and comfortable with the procedure/products and increase their
orders in the coming years.
Read more here:
AxoGen Still In The Doghouse, But The Opportunity Is Compelling
No comments:
Post a Comment